Fair Therapeutics Completes Phase IIb Trial for CFTR Modulator in Rare CF Variants
January 9, 2025
Fair Therapeutics B.V. has completed enrollment of its Phase IIb CHOICES trial, evaluating the novel CFTR triple modulator therapy, Diponecaftor, for adults with ultra-rare cystic